C-C motif chemokine 22 ligand (CCL22) concentrations in sera of gastric cancer patients are related to peritoneal metastasis and predict recurrence within one year after radical gastrectomy

Yin, Wei; Wang, Tie; Song, Hongjiang; Tian, Lining; Lyu, Gong-Wei; Zhao, Lei; Xue, Yingwei

doi:10.1016/j.jss.2016.11.067

Cited by 21 publications

(19 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…High levels of CXCR4, a receptor correlated with tumor malignancy, and CCL22, a member of the chemokine family, are related to migration, invasion, and metastasis in various tumors, leading to a poor prognosis and malignant progression [58][59][60][61]. Our results show that NPs 1 and NPs 2 decrease CXCR4 and CCL22 expression in the primary microenvironment, which indicates that our nanoparticulated DDSs act as important modulators of metastatic sites.…”

Section: Discussionmentioning

confidence: 62%

Effect of Oxaliplatin-Loaded Poly (d,l-Lactide-co-Glycolic Acid) (PLGA) Nanoparticles Combined with Retinoic Acid and Cholesterol on Apoptosis, Drug Resistance, and Metastasis Factors of Colorectal Cancer

et al. 2020

View full text Add to dashboard Cite

Apoptosis signaling pathways, drug resistance, and metastasis are important targets to develop new cancer treatments. We developed cholesterol-coated Poly(d,l-Lactide-co-Glycolic Acid) (PLGA) nanoparticles for effective encapsulation and delivery of retinoic acid and oxaliplatin to analyze their antitumor activity in colorectal cancer. The cell viability and proliferation of tumoral cells lines (CT-26 and SW-480) decreased when compared to control in vitro after treatment with the nanoparticles. In addition, apoptosis of CT-26 cells increased. Importantly, cytoprotection of nontumor cells was detected. Expression of pro-apoptotic proteins was upregulated, while anti-apoptotic proteins were downregulated either in vitro or in vivo. In addition, drug resistance and metastasis factors were downregulated in vivo. Human colorectal tumors that highly expressed BCL-2 and Ki-67 had a greater tendency towards death within 60 months. Our results show that loading oxaliplatin combined with retinoic acid and cholesterol in a nanoparticle formulation enables determination of optimal antitumor activity and subsequent treatment efficacy.

show abstract

Section: Discussionmentioning

confidence: 62%

Effect of Oxaliplatin-Loaded Poly (d,l-Lactide-co-Glycolic Acid) (PLGA) Nanoparticles Combined with Retinoic Acid and Cholesterol on Apoptosis, Drug Resistance, and Metastasis Factors of Colorectal Cancer

et al. 2020

View full text Add to dashboard Cite

show abstract

“…Since the immunohistochemistry score of CCL22 was positively correlated with its serum concentration and tumor bed was the main source of serum CCL22 in gastric cancer. 40 It seemed possible that cancer cells could release CCL22 to tame tumor microenvironment and to recruit Tregs, which would eventually risk people a higher possibility of immune escape and result in a lower survival rate and therapy resistance. Besides, previous studies found that cancer cells could secret cytokines to recruit and transform immune cells such as fibroblasts, neutrophils, and macrophages, which had a great importance in the immunosuppressive microenvironment.…”

Section: Discussionmentioning

confidence: 99%

C-C motif chemokine 22 predicts postoperative prognosis and adjuvant chemotherapeutic benefits in patients with stage II/III gastric cancer

Líu

et al. 2018

OncoImmunology

View full text Add to dashboard Cite

Immune molecules, which have been found to be important in tumor microenvironment, seem prospective in tumor therapy, but they are still not effective enough to use in clinical practice. C-C motif chemokine 22 (CCL22) exists in various malignancies and correlates with migration of regulatory T cells, but its clinical significance in gastric cancer is still unclear. In this study, a combined data set of 466 patients with gastric cancer after surgical resection, comprised of a discovery (n = 319) and a validation data set (n = 147), was enrolled. CCL22 expression was assessed by immunohistochemical staining and we evaluated prognostic values of CCL22 staining and clinical outcomes with use of Kaplan-Meier curve and Multivariate Cox regression analysis. Positive CCL22 expression predicted adverse overall survival independent of traditional pathological grade. Multivariate analysis defined CCL22 and TNM stage as two independent prognostic factors for overall survival. Besides, in patients with TNM stage II/III disease, the rate of overall survival was higher among patients with CCL22-positive tumors who were treated with 5-fluorouracil based adjuvant chemotherapy than that among those who were not ( = 0.012, < 0.001 and < 0.001, in discovery, validation and combined data set). But for these with CCL22-negative tumors, whether to undergo adjuvant chemotherapy showed no statistical significance ( = 0.595, = 0.085 and P = 0.252, respectively). To conclude, CCL22 was identified as an independent adverse prognostic immunobiomarker for patients with gastric cancer after surgery, which is associated with tumor-infiltrating immunocytes and could be incorporated into TNM staging system to redefine a high-risk subgroup who were more likely to benefit from 5-fluorouracil based adjuvant chemotherapy.

show abstract

“…Subsequently, plates were blocked with 10% FBS for 2 h at room temperature. By using a mouse CD8 + T cell isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), tumor-infiltrating CD8 + T cells were isolated from single-cell suspensions that were achieved by a mouse tumor dissociation kit (Miltenyi Biotec) following the manufacturer's instruction (22). Purified CD8 + T cells were seeded into the above-mentioned ELISpot plates (10 5 cells/well) and stimulated overnight with or without live tumor cells according to the implanted cell line (2 × 10 4 per well).…”

Section: Enzyme-linked Immunospot (Elispot)mentioning

confidence: 99%

“…Single-cell suspensions from tumors were achieved by enzyme digestion and mechanical dissociation using a commercial kit (Miltenyi Biotec) (22). Briefly, tumors were removed from mice when indicated and minced into small pieces of 2-4 mm in diameter.…”

Section: Flow Cytometrymentioning

confidence: 99%

Therapy With Carboplatin and Anti-PD-1 Antibodies Before Surgery Demonstrates Sustainable Anti-Tumor Effects for Secondary Cancers in Mice With Triple-Negative Breast Cancer

Gao

Wang

et al. 2020

Front. Immunol.

Self Cite

View full text Add to dashboard Cite

Patients with triple-negative breast cancer (TNBC) suffer an unfavorable prognosis. Carboplatin (CBDCA) as a cytotoxic reagent has been widely administered to patients with cancer including TNBC. Programmed cell death protein 1 (PD-1) is an immune checkpoint, blockade of which unleashes T cell functions that kill cancer cells. However, the efficacy of CBDCA combined with anti-PD-1 antibodies in TNBC has not been determined. Patient-derived xenografts (PDX) were implanted to immune-deficient mice. Three mouse TNBC cell lines (4T1, EMT6, and E0771) were seeded to immune-competent mice. Tumor volumes and survival rates were monitored. CBDCA and anti-PD-1 antibodies were administered by intra-peritoneal injection at designated time points. Total CD8 + T cells, memory CD8 + T cells, and CD103 + dendritic cells (DC) in the tumor were measured by flow cytometry. Tumor-specific CD8 + T cells were quantified by the ELISpot assay. Administration of CBDCA to PDX-bearing mice induced increased levels of tumor cell necrosis and reduced tumor size. Treatment with CBDCA and anti-PD-1 antibodies reduced TNBC tumor volumes and slightly improved survival rates. More importantly, therapy with CBDCA and anti-PD-1 antibodies before surgery showed a remarkably improved, sustainable protection against a secondary tumor after surgery by a CD8 +-T-cell-dependent manner, which required CCL4 expressed in the tumor and subsequently CD103 + DC recruited to the tumor microenvironment. Immunochemotherapy with CBDCA and anti-PD-1 antibodies before surgery improves the outcome of a secondary tumor after surgery via increasing the number of tumor-specific CD8 + T cells in the tumor microenvironment of murine TNBC. These results highlight the possibility to utilize this regimen in clinical practice.

show abstract

C-C motif chemokine 22 ligand (CCL22) concentrations in sera of gastric cancer patients are related to peritoneal metastasis and predict recurrence within one year after radical gastrectomy

Cited by 21 publications

References 33 publications

Effect of Oxaliplatin-Loaded Poly (d,l-Lactide-co-Glycolic Acid) (PLGA) Nanoparticles Combined with Retinoic Acid and Cholesterol on Apoptosis, Drug Resistance, and Metastasis Factors of Colorectal Cancer

Effect of Oxaliplatin-Loaded Poly (d,l-Lactide-co-Glycolic Acid) (PLGA) Nanoparticles Combined with Retinoic Acid and Cholesterol on Apoptosis, Drug Resistance, and Metastasis Factors of Colorectal Cancer

C-C motif chemokine 22 predicts postoperative prognosis and adjuvant chemotherapeutic benefits in patients with stage II/III gastric cancer

Therapy With Carboplatin and Anti-PD-1 Antibodies Before Surgery Demonstrates Sustainable Anti-Tumor Effects for Secondary Cancers in Mice With Triple-Negative Breast Cancer

Contact Info

Product

Resources

About